Grifols SA
Grifols SA is a biopharmaceutical company focused on plasma-derived medicines and related services for patients with chronic and rare diseases. Its business includes the collection and processing of human plasma, the manufacture of therapies and diagnostic products, and the operation of plasma donation and manufacturing infrastructure across multiple markets.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueMedicines manufactured from human plasma for chronic, rare and life-threatening conditions.
Therapies used in specialty care settings, often prescribed by physicians and hospitals.
Products and solutions used in blood screening, testing and transfusion workflows.
Operation of plasma donation centers and related donor-support infrastructure.
Customers
Grifols sells primarily to healthcare professionals, hospitals, blood banks and healthcare systems that prescribe, stock or administer plasma-derived therapies. It also serves plasma donors through its collection network and supports wholesalers, distributors and group purchasing organizations that help place its products in care settings. In the United States it also conducts patient education and awareness activities, but its medicines are prescription-based and not direct-to-consumer products.
Buy plasma-derived medicines and diagnostics for inpatient, outpatient and specialty treatment use.
Procure transfusion-related products and supply solutions for public healthcare needs.
Purchase and distribute Grifols products into hospital and specialty-care channels.
Provide plasma at collection centers; they are a supply-side customer/participant group critical to operations.
Indirect end users of prescribed plasma-derived therapies used in ongoing treatment.
Strategy
Grifols’ strategy centers on maintaining a trusted plasma-supply network, supporting physicians and patients with education, and securing approvals for manufacturing facilities and new indications. The company also emphasizes compliance-led marketing, stakeholder engagement and regulatory interaction because its business depends on prescription access, plasma-center authorization and quality standards.
Plasma supply is the core input to the company’s therapies and determines product availability.
Manufacturing and commercialization depend on health-authority approvals and ongoing quality oversight.
Prescribed therapies rely on diagnosis, access and clinical understanding rather than consumer advertising.
Geography
Grifols operates globally, with commercial activities and stakeholder engagement spanning the United States, Europe and other international markets. The company’s plasma collection, manufacturing, regulatory and commercial footprint makes geography important because donation access, health-system reimbursement and regulatory approvals differ by country. The reports also show specific U.S. direct-to-consumer educational initiatives alongside broad healthcare-professional marketing worldwide.
Risks
Grifols faces supply-chain and operational risk because its therapies depend on sufficient plasma collection, center authorization and quality-controlled manufacturing. It is also exposed to regulatory, litigation and compliance risk given the medical nature of its products, the scrutiny around promotional practices, and the need for approvals across multiple jurisdictions.
- Regulatory approval delaysImpact: HighLikelihood: High
Plasma centers, facilities and new indications require health-authority approvals.
Exposure - Plasma supply disruptionImpact: HighLikelihood: Medium
The business depends on a steady flow of donor plasma to manufacture medicines.
Exposure: Collection centers and manufacturing operations
- Goodwill and asset impairmentImpact: HighLikelihood: Medium
Management must test intangible and non-current assets for recoverability using estimates.
Exposure - Compliance and marketing scrutinyImpact: MediumLikelihood: High
The company promotes prescription products and must keep materials balanced and lawful.
Exposure: Healthcare-professional and patient-directed materials
Accounting
Judgemental itemsManagement must estimate recoverable amounts annually or when indicators arise.
Impact: Can create material non-cash charges if forecasts weaken.
Acquired assets and liabilities require valuation at closing and subsequent measurement.
Impact: Affects purchase accounting and future amortization or impairment.
Depreciation and amortization depend on management estimates of asset life.
Impact: Changes reported operating costs over time.
The reports reference contractual-obligation assessments and litigation-related matters.
Impact: May influence provisions and disclosed liabilities.
Similar listed companies
Publicly listed companies with a comparable business focus.
GRI Bio, Inc.
GRI · Pharmaceutical Preparations
Rigel Pharmaceuticals, Inc
RIGL · Pharmaceutical Preparations
Rigel Pharmaceuticals is a U.S.-based biotechnology company focused on therapies for hematologic disorders and cancer.
GRAIL, Inc.
GRAL · Services-Medical Laboratories
Takeda Pharmaceutical Company Limited
TAK · Pharmaceutical Preparations
Takeda Pharmaceutical is a Japan-headquartered biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing prescription medicines.
Geron Corporation
GERN · Pharmaceutical Preparations
Geron Corp is a U.S.-based biopharmaceutical company focused on developing and commercializing imetelstat, marketed as RYTELO, for patients with lower-risk myelodysplastic syndromes.
Prothena Corporation plc
PRTA · Pharmaceutical Preparations
Prothena Corp.
Last updated: 28/09/2026